Mortality associated with septic shock is thought to be a consequence of severe derangements in the cardiovascular system; with myocardial dysfunction playing a primary role. Indeed, reduced cardiac contractile function has been observed both in septic patients and experimental animal models of lipopolysaccharide (LPS)-induced sepsis. The cellular and molecular mechanisms responsible for these effects, however, remain incompletely understood.

Recent studies in rat and mouse models of sepsis have partially elucidated these mechanisms. One key factor that has emerged is high mobility group box 1 (HMGB1) protein, which serves as a late-phase mediator in the pathogenesis of sepsis. HMGB1 is an intranuclear protein that was originally identified as an important gene regulator. Following the activation of the inflammation cascade, HMGB1 is released from necrotic damaged cells and secreted by activated monocytes and macrophages. Its mechanism of action is presumably via its affinity for receptors for advanced glycation end-products, Toll-like receptor 2 and Toll-like receptor 4. HMGB1 binding to its receptors activates intracellular signaling pathways, such as the NF-κB pathway, which induce downstream cytokine release, thereby enhancing the inflammatory response.

LPS, a cell membrane component shed from Gram-negative bacteria, is a key mediator of septicemia and its pathogenic effects on the heart, but exactly how this endotoxin causes cardiac dysfunction remains largely unclear. We hypothesized that HMGB1 might be a key mediator in the pathogenesis of cardiac dysfunction and to test this, we exposed hearts from LPS-treated rats to recombinant HMGB1 protein.

**Methods**

Recombinant HMGB1 was purchased from Shino-Test Recombinant (Tokyo, Japan) and LPS (O127:B8) was obtained from Sigma (St Louis, MO, USA). All reagents were of the highest available analytical grade.

**Animals**

Male Wistar rats weighing 250–300 g (Kyudou, Saga, Japan) were used in all experiments. All rats received humane care in compliance with the National Institute of Health (NIH) guidelines and the Principles of Laboratory Animal Care. All animals were housed with free access to food and water.
Experimental Protocols

The rats were randomly assigned to 1 of 2 treatment groups. The 6 animals in the control group received an intravenous bolus injection of 0.9% NaCl solution alone. The 6 animals in the LPS group received an intravenous bolus injection of LPS dissolved in 0.9% NaCl solution (5mg/kg). All rats were killed under general 2% sevofluren anesthesia 12 h following injection. Tissue specimens were immediately removed surgically and processed.

Histological Analysis

Heart tissue specimens were instilled with 10% formalin. The samples were embedded in paraffin and cut into 4-μm sections for staining with hematoxylin and eosin.

Immunoblotting Analysis

The hearts were harvested from all animals. After the blood was washed out using saline perfusion, the heart was homogenized with a T-PER (Tissue Protein Extraction Reagent; Pierce, Rockford, IL, USA) in a polytron homogenator (IKA Labortechnik, Staufen, Germany). The homogenates were then centrifuged at 10,000 g for 5 min at 4°C. The concentration of protein in the collected supernatant was measured by absorbance at 562 nm using the BCA Protein Assay Regent system (Pierce).

For gel electrophoresis, equal quantities of protein (100 μg) were suspended in sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) buffer. Protein samples were boiled for 1 min and separated using a 10% SDS-polyacrylamide gel. Protein runs using SDS-PAGE were immediately electrotransferred to polyvinylidene difluoride membrane (PVDF) (Millipore, Bedford, MA, USA) at 60 V for 3 h in a wet transfer system containing 20 mmol/L Tris-HCl/0.2 mol/L glycine in 20% methanol as the transfer buffer. The membrane was blocked with 5% nonfat dry milk in Tris/Tween buffer for 1 h. The blot was then washed by rinsing with TBS/Tween 3 times for 10 min. The membrane was treated with enhanced chemiluminescence reagent (Amersham, Buckinghamshire, UK) and then exposed to X-ray film. After scanning the X-ray film, the band concentration was calculated by quantification of the integrated optical density using NIH Image J software package (NIH, Bethesda, MD, USA).

Measurement of HMGB1 Secretion

Serum samples were assayed using the ELISA sandwich method and 96-well plates that were precoated with monoclonal antibodies specific to rat HMGB1 (Shino-Test Corporation). The samples, negative controls, and diluted HMGB1 standard markers were added to each well. Detection of HMGB1 in the samples was performed according to the manufacturer’s protocols. The A450 values were determined using an ELISA reader.

Isolated Heart Perfusion and Assessment of Cardiac Function

Cardiac function was determined by a modified isovolumetric Langendorff technique as described elsewhere and expressed as left ventricular developed pressure (LVDP), left ventricular end-diastolic pressure (LVEDP), left ventricular (LV) +dP/dtmax, and LV–dP/dtmax. At the termination of the experiments, beating hearts were rapidly excised into oxygenated Krebs-Henseleit solution containing 11 mmol/L glucose, 2.0 mmol/L CaCl2, 4.3 mmol/L KCl, 25 mmol/L NaHCO3, 118 mmol/L NaCl, 1.2 mmol/L MgSO4, and 1.2 mmol/L KH2PO4. Normothermic retrograde perfusion was performed with this solution in an isovolumetric and nonrecirculating mode. The perfusion buffer was saturated with a gas mixture of 95% O2–5% CO2 at a pH of 7.4. Perfusion pressure was maintained at 75 mmHg.
A latex balloon was inserted through the left atrium into the left ventricle, and filled with water (0.18–0.28 ml). LVDP, LVEDP, +dP/dt max, and –dP/dt min were continuously recorded with a computerized pressure amplifier-digitizer (BIOPAC Systems, Inc, Goleta, CA, USA). After 20 min of perfusion (to reach equilibrium), the inotropic effects were measured in the presence of varying concentrations of recombinant HMGB1 added to the perfusion solution. Myocardial temperature was maintained at 37°C through the circulation of warm water.

**Statistical Analysis**

All descriptive data are presented as the means ± standard error of the mean. The data were analyzed by repeated measurement ANOVA for multiple comparisons, and by unpaired t-test for single comparisons. A p-value <0.05 was considered to be statistically significant.

**Results**

**Cardiac Tissue Pathology**

We investigated whether LPS-induced sepsis would affect cardiac histopathology. No histological alterations were observed, however, in either the control or the LPS-treated group (Figs 1A–D).

**HMGB1 Expression in Cardiac Tissue and Serum**

We next examined whether LPS treatment would affect the levels of HMGB1 in cardiac tissue and serum. At 12 h after LPS treatment, heart tissue was isolated and analyzed by immunoblotting. Levels of HMGB1 protein in tissue from LPS-treated animals were at least 2-fold higher than those in the control group (Figs 2A, B). Prior to LPS administration, HMGB1 was barely detectable in the sera of rats from either group. Following LPS injection, HMGB1 levels increased markedly, so that by 12 h post-injection the expression was higher than in the control group (Fig 3).

**Isolated Heart Perfusion and General Effects of LPS Treatment**

Heart rate (HR) did not differ between the control and LPS groups (Fig 4A), but LPS group animals demonstrated a higher LVEDP at 12 h after exposure to LPS compared with the control groups (Fig 4B). As shown in Fig 4C, hearts subjected to LPS exhibited a significant impairment of LVDP. LV+ dP/dt max, the rate of pressure rise during contraction (Fig 4D), was lower in the LPS group than in the control group (p<0.05). LV– dP/dt min, the maximum rate of relaxation (Fig 4E), was also lower in the LPS group (p<0.05). Twelve hours after exposure to LPS, the isolated hearts demonstrated significantly lower LVDPs.

**Effect of HMGB1 on Myocardial Function in Control Animals**

Perfusion with 0.1 μg/ml HMGB1 had no apparent effect on HR, LVEDP, LVDP, LV+ dP/dt max, or LV– dP/dt min (data not shown). We then investigated the effect of 1 and 10 μg/ml HMGB1 on cardiac performance in the control animals. Perfusion with 10 μg/ml HMGB1 had no effect on HR (Fig 4A), LVEDP (Fig 4B) or LV– dP/dt min (Fig 4E). It did, however, lead to small decreases in LVDP (Fig 4C) and LV+ dP/dt max (Fig 4D), although these changes were not significantly different.

**Effect of Combined LPS Treatment With HMGB1 on Myocardial Function**

After LPS treatment, hearts were removed and perfused with HMGB1 for a period of 10 min and cardiac function was measured. Perfusion with 1 or 10 μg/ml HMGB1 resulted in no changes in HR (Fig 4A). Perfusion of 0.1 μg/ml HMGB1 had no effect on HR, LVEDP, LVEDP, LV+ dP/
HMGB1 Induces Negative Inotropic Effect

Hearts perfused with HMGB1 at concentrations of 1 or 10 µg/ml, however, showed significantly increased LVEDP in the LPS group, compared with the control group (Fig 4B). In contrast, hearts perfused with HMGB1 at concentrations of 1 or 10 µg/ml showed markedly decreased LVDP (Fig 4C), LV+dP/dtmax (Fig 4D), and LV–dP/dtmin (Fig 4E), relative to the control group. These observed effects on cardiac function occurred in an HMGB1 dose-dependent manner. We next examined the effect of 10 µg/ml HMGB1 on hemodynamic parameters over time. All of the previously described effects were apparent within 1 min after exposure and remained relatively stable throughout the 10-min period of exposure (Figs 5A–D). After 10 min, HMGB1 was washed from the perfused hearts and all parameters immediately returned to baseline.

**Discussion**

Our results suggest that HMGB1 played an important role in causing decreased myocardial activity in a rat model of septic shock. Within 12 h of administration, LPS caused a significant increase in the level of HMGB1 in serum and cardiac tissue. In addition, recombinant HMGB1 repro-
duced the effects of LPS-induced septic shock on rat cardiac function. This study is the first to demonstrate that HMGB1 serves as a late mediator of endotoxin-induced cardiac dysfunction in vivo. Taken together, our findings indicate that HMGB1 must be locally present in cardiac tissue within 12 h after LPS challenge to cause cardiac dysfunction. This result is critical because cardiac dysfunction during sepsis is associated with poor outcome in both humans and animals.3–5 Several previous studies have shown that sepsis-associated cardiac dysfunction is primarily related to circulating myocardial depressant factors, including tumor necrosis factor (TNF)-\( \alpha \).15 However, because TNF-\( \alpha \) is a sentinel, rapid-response cytokine and is removed from the circulation several days before the resolution of myocardial dysfunction, it is clear that there are other mediators involved. HMGB1, widely known as a nuclear structural protein, has been identified as a late mediator of delayed endotoxin lethality16 and is an excellent candidate protein to exert these effects. In humans, patients with sepsis or systemic inflammatory response syndrome have significantly elevated plasma levels of HMGB1.16

HMGB1 is a nuclear protein that acts as a DNA chaperone in normal cells and promotes DNA–protein interactions.37 It has been shown to play an important role in various types of inflammation and is thought to contribute to the pathology and mortality of sepsis, presumably as a late phase inflammatory mediator.18 In addition, HMGB1 is an important mediator of cell death, and its expression occurs at a relatively late phase following injury.16

In this study, we found that HMGB1 expression was elevated in cardiac tissue and serum 12 h after LPS administration in a rat septic shock model. In this model, the hearts from LPS-treated animals showed increased LVEDP and decreased LVDP, LV+dP/dtmax, and absolute value of –dP/dtmin, compared with the hearts from untreated rats. We also examined the direct effect of HMGB1 on cardiac function following endotoxin exposure by perfusing recombinant HMGB1 into the hearts from LPS-treated animals. This treatment did not affect HR, but it did augment the increase in LVEDP normally seen in LPS-treated animals, as well as further augment the decrease in LVDP, LV+dP/dtmax, and the absolute value of –dP/dtmin in a dose-dependent manner. Recent studies reported that exogenous HMGB1 improved cardiac function and myocyte regeneration after infarction;19,20 however, in our model of septic shock, HMGB1 had a negative inotropic effect. This is the first report of exogenous HMGB1 having an inhibitory effect on cardiac function in a septic shock model, which is different from other reports. The mechanism by which HMGB1 inhibits cardiac function is unknown, and thus requires further study.

In summary, our results suggest that HMGB1 plays a critical role in the myocardial dysfunction that follows endotoxin-induced septic shock. Our study examined only the effects of recombinant HMGB1 in the endotoxin-treated rat heart. Further extension of these studies may confirm that HMGB1 could be a new therapeutic target for ameliorating myocardial dysfunction in septic shock.

References

1. Krishnagopalan S, Kumar A, Parrillo JE, Kumar A. Myocardial dys-


11. Hagiwara S, Iwasaka H, Matumoto S, Noguchi T, Nafamostat mesi-


